RNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RNA is NOT a good buy right now. Despite a still-bullish longer-term trend (SMA5>SMA20>SMA200) and strong YoY revenue growth in 2025/Q3, near-term momentum is weakening (MACD histogram negative and deteriorating), options flow is strongly defensive (put-heavy), and insider selling has surged. For an impatient buyer who won’t wait for a cleaner entry, the current setup is more “stand aside/hold” than “buy now.”
Intellectia Proprietary Trading Signals
Trend is mixed: the medium/long-term structure remains constructive with bullish moving average alignment (SMA_5 > SMA_20 > SMA_200), but short-term momentum is fading. MACD histogram is -0.112 (below zero) and negatively expanding, which typically signals increasing downside/weakening momentum. RSI_6 at ~43.48 is neutral but leaning weak (not oversold). Price (72.47) is sitting just below the pivot (72.571) and very near first support (S1 72.441 / S2 72.361); a decisive break below support would confirm the near-term weakness, while reclaiming the pivot would be the first sign buyers are regaining control. Pattern-based projection is modestly bullish over 1W–1M, but current momentum indicators don’t support aggressive buying today.
supports the longer-term uptrend; 2025/Q3 revenue surged (+434% YoY) indicating meaningful commercialization/partnering progress; very low IV percentile implies option premiums are cheap and can amplify returns if a positive catalyst emerges; pattern-based odds favor gains over the next week/month (projected +2.46% next week, +9.02% next month).
Insiders are selling aggressively (selling amount up ~200.63% over the last month), which is a notable near-term confidence overhang; MACD is negative and worsening, signaling deteriorating momentum; options flow is strongly put-dominated (bearish/hedging tone); no recent news catalysts in the last week to counteract the defensive positioning; company is still deeply loss-making in absolute terms (net income and EPS remain negative).
Latest reported quarter: 2025/Q3. Revenue rose to 12.475M (+434.03% YoY), indicating sharp top-line acceleration. Profitability remains weak: net income was -174.442M and EPS -1.27 (both still negative, though the dataset indicates YoY improvement in these metrics). Gross margin is reported at 100, consistent with biotech-style revenue (e.g., collaboration/other high-margin revenue) rather than mature product cost structure—strong growth, but still not a self-funding earnings profile yet.
No analyst rating trend or price target change data was provided, so a verified Wall Street consensus shift can’t be assessed here. With the available inputs, the ‘pro’ case would center on accelerating revenue and an intact longer-term uptrend, while the ‘con’ case is near-term momentum deterioration plus heavy put positioning and increased insider selling.
